The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000525381p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
27/01/2026
Date registered
Help: Date registered
29/04/2026
Date last updated
Help: Date last updated
29/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
29/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The effect of treating bowel cancer presenting with bowel obstruction with relief of obstruction and chemotherapy prior to surgery on long-term abdominal recurrence risk
Scientific title
Comparing the effect of Diversion or Intestinal stenting followed by Neoadjuvant systemic chemotherapy versus upfront surGery for Obstructing colon cancer (DINGO) on peritoneal disease recurrence: a multicentre open-label randomised controlled trial
Additional trial identifiers [1] 316377 0
Nil known
Universal Trial Number (UTN)
Trial acronym
DINGO
Related trial records

Health condition
Health condition(s) studied:
Malignant colonic obstruction 340466 0
Condition category
Condition code
Cancer 336671 336671 0 0
Bowel - Back passage (rectum) or large bowel (colon)
Surgery 336672 336672 0 0
Other surgery

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Bridge to surgery strategy (either colonic stenting or stomal diversion) with neoadjuvant systemic chemotherapy once effective relief of obstruction obtained, followed by definitive surgery (Intervention group)
vs upfront surgical resection (Standard of care group)
Allocation of which bridge-to-surgery intervention patients in the BTS arm receive will be at clinical discretion of the treating surgeon based on anatomical location of the tumour.
Neoadjuvant systemic chemotherapy will be FOLFOX for 6 cycles, each cycle delivered at fortnightly intervals. (Oxaliplatin 85mg/m2 over 120 minutes IV, leucovorin 50mg/m2 IV and 5-fluorouracil 400mg/m2 IV) given fortnightly in Oncology day suite. All patients will be discussed at their hospital's multidisciplinary meeting (MDM) prior to commencing neoadjuvant therapy.
Neoadjuvant therapy will be overseen by the patient's Medical Oncologist in conjunction with their treating surgeon.
Electronic medical records will be used to regularly review adherence to neoadjuvant therapy or deviation from trial protocol.
Intervention code [1] 333040 0
Treatment: Surgery
Description of the comparator or control
Upfront surgical resection (Standard of care group)
This will be either right hemicolectomy, left hemicolectomy, anterior resection, or subtotal colectomy. This entails a procedure under general anaesthesia to remove the segment of colon where the obstructing tumour is located, along with the lymph nodes. Depending on which operation is required procedure time may range from 2-4 hours. Depending on the degree of obstruction the procedure may be undertaken via an open or minimally invasive approach - this will be at the discretion of the treating surgeon. The surgeon may choose to join (anastomose) the remaining ends of bowel together, without the need for a stoma; join the bowel ends together and place a stoma; or not join the bowel ends together and place a stoma. Typical hospital stay after surgery ranges from 7-14 days.
The intervention will be administered by a Colorectal or General Surgeon with specialist recognition.
Operative reports will be used to monitor adherence to the intervention.
Control group
Active

Outcomes
Primary outcome [1] 344185 0
Peritoneal disease recurrence
Timepoint [1] 344185 0
Baseline; 3 months, 6 months, 12 months, 18 months, 24 months (imaging assessments) post index presentation with symptoms of bowel obstruction.
Secondary outcome [1] 456965 0
Recurrence-free survival
Timepoint [1] 456965 0
Baseline; 3 months, 6 months, 12 months, 18 months, 24 months (imaging assessments) post index presentation with symptoms of bowel obstruction
Secondary outcome [2] 456966 0
Overall survival
Timepoint [2] 456966 0
Baseline; 3 months, 6 months, 12 months, 18 months, 24 months (clinical assessments) post index presentation with symptoms of bowel obstruction

Eligibility
Key inclusion criteria
Eligible participants are adults (18 years of age or older) with clinically and/or endoscopically obstructed colon adenocarcinoma, considered potentially resectable with curative intent and suitable for either upfront resection or a bridge-to-resection strategy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion criteria include rectal cancer, evidence of diffuse peritoneal carcinomatosis at presentation, unresectable metastatic disease, or contraindications to either treatment strategy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central computer-based randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random sequence with variable block sizes.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Primary outcome analysis
Time to peritoneal recurrence will be analysed using a Cox proportional hazards regression model, with treatment group as the primary covariate.
To account for potential correlation of outcomes within participating centres, robust sandwich standard errors clustered by centre will be used. Results will be reported as hazard ratios with 95% confidence intervals.
Sensitivity analyses
To assess robustness to alternative assumptions regarding centre-level heterogeneity, a shared frailty Cox model with a random centre effect will be performed as a sensitivity analysis.
Additional sensitivity analyses will include per-protocol analyses excluding major protocol deviations and competing-risk analyses treating death or non-peritoneal recurrence as competing events, where appropriate.
Assumptions and diagnostics
The proportional hazards assumption will be assessed using Schoenfeld residuals and time-dependent covariate testing. Where violations are identified, appropriate sensitivity analyses will be undertaken.
Missing data
Participants without documented peritoneal recurrence will be censored at the date of last follow-up. Efforts will be made to minimise missing data through structured follow-up. Missing baseline covariate data will be handled using appropriate imputation methods where required.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 320988 0
Hospital
Name [1] 320988 0
Alfred Health
Country [1] 320988 0
Australia
Primary sponsor type
Hospital
Name
Alfred Health
Address
Country
Australia
Secondary sponsor category [1] 323685 0
Hospital
Name [1] 323685 0
Royal Melbourne Hospital
Address [1] 323685 0
Country [1] 323685 0
Australia
Secondary sponsor category [2] 323687 0
Hospital
Name [2] 323687 0
Peter MacCallum Cancer Centre
Address [2] 323687 0
Country [2] 323687 0
Australia

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 319520 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319520 0
Ethics committee country [1] 319520 0
Australia
Date submitted for ethics approval [1] 319520 0
13/05/2026
Approval date [1] 319520 0
Ethics approval number [1] 319520 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147590 0
Ms Lauren O'Connell
Address 147590 0
Department of Surgical Oncology, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne VIC 3000
Country 147590 0
Australia
Phone 147590 0
+61 452306640
Fax 147590 0
Email 147590 0
Contact person for public queries
Name 147591 0
Lauren O'Connell
Address 147591 0
Department of Surgical Oncology, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne VIC 3000
Country 147591 0
Australia
Phone 147591 0
+61 452306640
Fax 147591 0
Email 147591 0
Contact person for scientific queries
Name 147592 0
Lauren O'Connell
Address 147592 0
Department of Surgical Oncology, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne VIC 3000
Country 147592 0
Australia
Phone 147592 0
+61 452306640
Fax 147592 0
Email 147592 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
After completion of first data analysis
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.